Kurome Therapeutics
Manufacturing · Ohio, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3536 Edwards Rd Uppr Ste 100, Cincinnati...Phone Number
(513) 445-3852Website
www.kurometherapeutics.comRevenue
$6.4 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Kurome Therapeutics
Edgewater Group LLC is a professional organization specializing in affordable housing ownership, development, finance, management, and energy efficiency programs. The company is composed of experienced housing professionals who have collaborated with government programs to assist low-income multifamily residents. Their extensive portfolio of apartment properties showcases their commitment to enhancing the comfort and safety of affordable housing residents while adding value for property owners and investors. Additionally, Edgewater Group focuses on reducing energy consumption to promote a greener environment.Explore more
Kurome Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Kurome Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Kurome Therapeutics has new funding data
Product Launch: Get notified when Kurome Therapeutics launches new products
Check out if Kurome Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Kurome Therapeutics had a recent Job posting/layoffs
Check if Kurome Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Kurome Therapeutics
Kurome Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Kurome Therapeutics recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Kurome Therapeutics
Compare insights from companies similar to Kurome Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Kurome Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Kurome Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Kurome Therapeutics.
Kurome Therapeutics financials insights
Gather financial insights about Kurome Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$15M
Kurome Therapeutics Tech Stack
A closer look at the technologies used by Kurome Therapeutics
See more technologies
Kurome Therapeutics News & Media
CORRECTING and REPLACING Kurome Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for KME-0584 for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS)
CINCINNATI--(BUSINESS WIRE)--Headline of release should read: Acute Myeloid Leukemia (instead of Acute Myeloid Lymphoma). The updated release reads: KUROME THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR KME-0584 FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) AND HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS) Entering the clinic in the second half of 2024, KME-0584, an IRAK1/4/panFIt3 Inhibitor is a first in class investigational drug for relapsed/refractoryKurome Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for KME-0584 for the Treatment of Acute Myeloid Lymphoma (AML) and High-Risk Myelodysplastic Syndromes (MDS)
CINCINNATI--(BUSINESS WIRE)--Kurome Therapeutics Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared the IND for KME-0584, allowing the company to proceed with a Ph1 clinical trial in relapsed/refractory (R/R) AML and high-risk (HR) MDS patients. Kurome plans to initiate the clinical trial in the latter half of 2024. “This is a major milestone for the Kurome team and our collaborators and validates our unique approach to AML and MDSKurome Therapeutics Closes $15 Million Series A Financing to Develop Targeted Kinase Inhibitors for Treatment of Hematopoietic Cancers
CINCINNATI--(BUSINESS WIRE)-- #biohealth--Funding supports the pre-clinical advancement of dual IRAK1/4 and panFLT3 inhibitors to target cancer cells that evade therapy and chemotherapy drugs.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Kurome Therapeutics
Sign Up For FreeTo access detailed company insights
Edgewater Group LLC is a professional organization specializing in affordable housing ownership, development, finance, management, and energy efficiency programs. The company is composed of experienced housing professionals who have collaborated with government programs to assist low-income multifamily residents. Their extensive portfolio of apartm... Read More
